Kenji Hashimoto Selected Research

traxoprodil mesylate

8/2009	Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder".
6/2004	Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenji Hashimoto Research Topics

Disease

133	Schizophrenia (Dementia Praecox) 06/2022 - 02/2002
39	Major Depressive Disorder (Major Depressive Disorders) 04/2021 - 07/2003
35	Inflammation (Inflammations) 04/2022 - 02/2013
33	Psychotic Disorders (Schizoaffective Disorder) 10/2022 - 02/2002
27	Mental Disorders (Mental Disorder) 01/2022 - 01/2006
27	Cognitive Dysfunction 10/2021 - 05/2004
25	Bipolar Disorder (Manic Depressive Psychosis) 01/2022 - 05/2004
19	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 04/2002
18	Mood Disorders (Mood Disorder) 01/2022 - 10/2002
18	Neoplasms (Cancer) 05/2021 - 01/2006
14	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2022 - 04/2010
11	Infections 01/2022 - 01/2012
11	Autistic Disorder (Autism) 12/2021 - 12/2006
10	Treatment-Resistant Depressive Disorder 01/2022 - 01/2005
10	Feeding and Eating Disorders (Eating Disorder) 02/2017 - 08/2003
8	Parkinson Disease (Parkinson's Disease) 09/2022 - 01/2018
8	Anhedonia 01/2021 - 01/2018
7	Dementia (Dementias) 05/2022 - 04/2013
7	Stroke (Strokes) 04/2022 - 03/2011
7	Treatment-Resistant Schizophrenia 12/2021 - 09/2012
7	Delirium 10/2021 - 01/2010
7	Pain (Aches) 12/2020 - 01/2011
7	Breast Neoplasms (Breast Cancer) 06/2017 - 07/2010
6	COVID-19 02/2022 - 01/2020
6	Neoplasm Metastasis (Metastasis) 01/2019 - 11/2006
5	Tardive Dyskinesia 12/2021 - 01/2012
5	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2021 - 10/2007
5	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 12/2008
5	Accidental Injuries 01/2015 - 04/2009
4	Body Weight (Weight, Body) 01/2022 - 08/2006
4	Disease Progression 01/2022 - 04/2013
4	Sepsis (Septicemia) 01/2022 - 04/2010
4	Neuralgia (Stump Neuralgia) 12/2020 - 01/2017
4	Hemorrhage 09/2019 - 01/2009
4	Prodromal Symptoms 01/2019 - 12/2009
4	Anorexia Nervosa 02/2017 - 08/2003
4	Panic Disorder (Panic Attack) 10/2007 - 06/2004
3	Autism Spectrum Disorder 04/2022 - 01/2020
3	Splenomegaly 01/2022 - 10/2021
3	Atrial Fibrillation 01/2022 - 01/2021
3	Osteoporosis 01/2022 - 01/2020
3	Nervous System Diseases (Neurological Disorders) 01/2022 - 02/2007

Drug/Important Bio-Agent (IBA)

47	Antidepressive Agents (Antidepressants)IBA 06/2022 - 10/2002
43	Brain-Derived Neurotrophic Factor (BDNF)IBA 09/2022 - 07/2003
40	Pharmaceutical PreparationsIBA 06/2022 - 06/2003
39	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2022 - 02/2002
38	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2003
36	Antipsychotic Agents (Antipsychotics)IBA 01/2021 - 02/2002
34	Ketamine FDA LinkGeneric 08/2022 - 02/2002
27	N-Methylaspartate (NMDA)IBA 01/2022 - 02/2002
26	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2004
23	Serine (L-Serine)FDA Link 01/2020 - 06/2003
22	Fluvoxamine (Luvox)FDA LinkGeneric 09/2022 - 03/2007
21	Sigma-1 ReceptorIBA 09/2022 - 03/2007
17	Dopamine (Intropin)FDA LinkGeneric 12/2021 - 06/2005
16	Glutamic Acid (Glutamate)FDA Link 05/2017 - 02/2002
15	Glycine (Aminoacetic Acid)FDA LinkGeneric 02/2015 - 02/2002
14	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2019 - 10/2007
14	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 11/2016 - 04/2002
12	Biological ProductsIBA 01/2020 - 06/2005
10	Epoxide HydrolasesIBA 04/2022 - 03/2016
10	EsketamineIBA 01/2022 - 01/2016
10	EnzymesIBA 12/2019 - 09/2002
9	Tropisetron (Navoban)IBA 07/2015 - 07/2005
8	Amino Acids FDA Link 01/2020 - 12/2006
8	Glutamine (L-Glutamine)FDA Link 12/2015 - 01/2005
8	Minocycline (Cyclops)FDA LinkGeneric 11/2015 - 09/2007
7	Therapeutic UsesIBA 04/2022 - 02/2003
7	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 04/2022 - 01/2013
7	ifenprodilIBA 01/2022 - 06/2004
7	LipopolysaccharidesIBA 01/2022 - 02/2013
7	D-Amino-Acid Oxidase (D-Amino Acid Dehydrogenase)IBA 04/2017 - 06/2005
6	sulforaphaneIBA 03/2021 - 04/2015
6	Messenger RNA (mRNA)IBA 01/2021 - 01/2008
6	Anti-Bacterial Agents (Antibiotics)IBA 08/2020 - 11/2010
6	Serotonin (5 Hydroxytryptamine)IBA 11/2017 - 10/2002
6	brexpiprazoleIBA 11/2017 - 09/2014
6	AntioxidantsIBA 09/2014 - 02/2002
6	Glutathione (Reduced Glutathione)IBA 10/2011 - 02/2002
5	CytokinesIBA 01/2022 - 01/2016
5	LigandsIBA 01/2020 - 01/2006
5	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2020 - 11/2013
5	Methamphetamine (Desoxyn)FDA LinkGeneric 01/2018 - 05/2005
4	Nasal SpraysIBA 01/2022 - 01/2019
4	AcidsIBA 01/2022 - 03/2006
4	salicylhydroxamic acid (SHAM)IBA 03/2020 - 01/2018
4	Haloperidol (Haldol)FDA LinkGeneric 10/2019 - 06/2004
4	Epidermal Growth Factor (EGF)IBA 01/2016 - 06/2005
4	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2015 - 04/2010
4	Clozapine (Clozaril)FDA LinkGeneric 10/2014 - 02/2003
4	Formaldehyde (Formol)FDA Link 09/2012 - 01/2011
4	Phencyclidine (Angel Dust)IBA 01/2012 - 02/2002
3	SynucleinsIBA 09/2022 - 01/2018
3	Poly I-CIBA 06/2022 - 03/2006
3	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 12/2021 - 01/2018

Therapy/Procedure

22	Therapeutics 01/2022 - 06/2005
10	Drug Therapy (Chemotherapy) 01/2015 - 03/2007
4	Aftercare (After-Treatment) 07/2020 - 06/2005
4	Transcranial Magnetic Stimulation 01/2020 - 01/2016
4	Secondary Prevention 01/2015 - 04/2010